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OBJECTIVE — To evaluate A1C for screening and diagnosis of undiagnosed type 2 diabetes
deﬁned by oral glucose tolerance testing in clinical and general populations.
RESEARCH DESIGN AND METHODS — A1C cut offs (5.5% to rule out diabetes;
7.0%toruleindiabetes)werederivedfromaclinicalgroup(MelbournePathology[MP]group:
n  2,494; undiagnosed diabetes 34.6%) and then evaluated in a population-based sample
(AusDiab group: n  6,015; undiagnosed diabetes 4.6%).
RESULTS — For diabetes in the MP and AusDiab groups, A1C at 5.5% gave sensitivities of 98.7
and83.5%,whileA1Cat7.0%gavespeciﬁcitiesof98.2and100%,respectively.Many(61.9–69.3%)
with impaired A1C (5.6–6.9%) in both populations had abnormal glucose status.
CONCLUSIONS — A1C 5.5% and 7.0% predicts absence or presence of type 2 diabetes,
respectively, while at A1C 6.5–6.9% diabetes is highly probable in clinical and population settings.
A high proportion of people with impaired A1C have abnormal glucose status requiring follow-up.
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W
ith current screening tools (fast-
ing plasma glucose [FPG] with
orwithoutoralglucosetolerance
test [OGTT]), the prevalence of undiag-
nosed diabetes in Australia remains high
(1). A1C provides a practical alternative
for screening (2,3). It is more convenient
and reproducible than is blood glucose
(3,4). As optimal cut offs are still in de-
bate,weexplorehereA1Clevelsthatcon-
ﬁdently rule out and rule in diabetes in
two different Australian populations.
RESEARCH DESIGN AND
METHODS— Westudiedtwopopula-
tions. The clinical population, Melbourne
Pathology(MP)group,includedallpatients
referred by medical practitioners for an
OGTTin2003–2008toastate-wideprivate
pathology service (MP Services, Australia);
the AusDiab population comes from a na-
tionalpopulation-basedstudy(2004–2005
AusDiab follow-up) (5). Only people with
concurrent A1C and OGTT results are in-
cluded here (MP group: n  2,494; Aus-
Diab: n  6,014). Glucose status was
classiﬁedbyAmericanDiabetesAssociation
criteria for OGTT (6).
A1C was determined either by Diabe-
tes Control and Complications Trial
(DCCT)-aligned (7) cation-exchange
chromatography (MP population) or by
boronate afﬁnity chromatography with
values converted to DCCT-aligned A1C
(5) (AusDiab). Plasma glucose was mea-
sured using hexokinase.
RESULTS
A1C cut offs deﬁned from the MP
population
Among those with undiagnosed diabetes
(34.6%) by OGTT criteria in the MP pop-
ulation, A1C at the 2.5th percentile was
5.6%. A1C 5.5% was thus chosen to
rule out diabetes. For those without dia-
betes (65.4%), A1C at the 97.5th percen-
tile was 6.9%. A1C 7.0% was thus
chosen to rule in (diagnose) diabetes.
Applying A1C cut offs to the MP
population (34.6% undiagnosed
diabetes)
Applyingtheabovecutoffs,atotal35.2%
of the MP population had diabetes ruled
in or ruled out (Fig. 1A), while the re-
maining 64.8% had an impaired A1C of
5.6–6.9%. From those with impaired
A1C,61.9%hadabnormalglucosestatus.
For diabetes, A1C at 5.5% provided high
sensitivity(97.8%)andhighnegativepre-
dictive value (NPV) (95.8%), while A1C
at 7.0% gave high speciﬁcity (98.2%) and
high positive predictive value (PPV)
(92.9%). Using the recommended cut off
of 6.5% (3), speciﬁcity decreased to
88.8% and the PPV decreased to 76.8%.
Applying A1C cut offs to the
AusDiab population (4.6%
undiagnosed diabetes)
Applying the same cut offs, a total 75.9%
of the AusDiab population had diabetes
ruled in or ruled out (Fig. 1B), while the
remaining 24.1% had impaired A1C.
From those with impaired A1C, 69.3%
had abnormal glucose status. For diabe-
tes, A1C at 5.5% provided moderate sen-
sitivity (83.5%) but high NPV (99.0%),
sincediabetesprevalencewaslowerinthe
AusDiab than in the MP population. A1C
at 7.0% gave 100% speciﬁcity and 100%
PPV. By dropping the cut off to 6.5%,
speciﬁcity remained 99.9%, with PPV
near 100%.
CONCLUSIONS — Our study sup-
ports recommendations to use A1C for
diabetes screening and diagnosis (2,3).
Using two, rather than one, cut off values
for A1C achieved high sensitivity for
screening plus optimal speciﬁcity for dia-
betes diagnosis. We also show the high
probability that those with impaired A1C
have abnormal glucose status.
Single A1C cut offs have limited clin-
ical utility in identifying those people
with abnormal blood glucose levels. The
most commonly reported single A1C cut
off obtained from reported receiver-
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6.1%, which gives sensitivities of 78–
81%, with speciﬁcities of 79–84% (8). In
our MP population, the ROC curve–
identiﬁed optimal A1C of 6.2% gave a
sensitivity of 82.2% and speciﬁcity of
78.8% (Z.X.L, unpublished data) but
yielded a reduced PPV (67.2%) and NPV
(89.3%).
We therefore apply two proposed cut
offs. The lower was chosen for its high
NPV, as diabetes is ruled out with high
conﬁdence (with A1C 5.5%, NPV was
95% in both clinical and population
settings).ApplyinganA1Cof5.5%toNa-
tional Health and Nutrition Examination
Survey (NHANES) data generated a sen-
sitivity of 92% and speciﬁcity of 30%
from the published ROC curve (9). This
gave an NPV of 99% (assuming 3.4%
undiagnosed diabetes) and agrees with
our ﬁnding that diabetes is very unlikely in
individuals with A1C 5.5%. Our 7.0%
cut off for diabetes diagnosis is higher than
the 6.5% recommended cut off (2,3) but
was chosen to optimize speciﬁcity.
For those with impaired A1C, the
prevalence of diabetes increases as A1C
increases. A1C is a continuous variable
for diabetes and any cut off values chosen
are somewhat arbitrary. From our data,
people with A1C 5.6–6.0% were more
likely to have either normoglycemia or
pre-diabetes (impaired fasting glucose
and/or impaired glucose tolerance) than
diabetes, consistent with NHANES,
where A1C 5.5–6.0% excluded diabetes
in moderate but not high-risk individuals
(10). Thus, those with an A1C of 5.6–
6.0% would probably require education
and lifestyle modiﬁcation to prevent pro-
gressiontodiabetes(11)plusretestingev-
ery 6–12 months. Also in our study,
people with an A1C of 6.1–6.4% were
more likely to have pre-diabetes or diabe-
tes than normoglycemia, while among
those with a A1C of 6.5–6.9%, diabetes
was highly probable. Thus, individuals
with an A1C of 6.1–6.9% may require an
OGTT to conﬁrm their glycemic status
plus lifestyle education and regular mon-
itoring as for people with pre-diabetes.
For those with an A1C 6.5%, screening
for retinopathy is also necessary (2).
A1C as a screening/diagnostic tool
has some limitations (3). The main issues
are method bias, which is now being ad-
dressed by Internation Federation of
Clinical Chemistry standardization (12)
and certain confounding medical condi-
tions (hemoglobinopathies and anemia).
Most new A1C methods can identify or
are unaffected by hemoglobinopathies.
Anemia is also readily identiﬁable.
The cost of A1C has also been raised
as a concern. While A1C analysis, per se,
is more expensive than for glucose, the
overalldifferencesaresmalloncethecosts
for blood collection are accounted for.
From our own estimates, total costs are
AUD $10.20 for A1C compared with
AUD $8.80 for FPG and AUD $12.10 for
a two-point collection of OGTT. These
cost comparisons are consistent with re-
ports from other countries (13–15). Fur-
ther, the time and inconvenience to
patients in having to fast for an OGTT
cannot be ignored.
A1C 5.5% and 7.0% predicts
with 97.5% conﬁdence the absence or
Figure 1—Application of the A1C cut offs to screen or diagnose diabetes in a clinical group (MP
population, n  2,494, undiagnosed diabetes 34.6%) (A) and in a national population-based
group (AusDiab population, n  6,014, undiagnosed diabetes 4.6%) (B).
A1C as a screening tool for diabetes
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OGTTasareference.Manywithimpaired
A1C have pre-diabetes, while diabetes is
highly probable when A1C reaches 6.5–
6.9%. Impaired A1C thus requires fol-
low-up and lifestyle modiﬁcation.
AlthoughthecostofA1Cisslightlyhigher
than for FPG, the overall efﬁciency of us-
ing A1C as a ﬁrst line for diabetes screen-
ing may facilitate early diagnosis and
reduce the health burden associated with
diabetes complications.
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